GHK-Cu: A Copper Carrier Built Into Collagen

The short version

GHK-Cu stands for Glycyl-L-Histidyl-L-Lysine copper(II) complex. You will also see it called copper tripeptide-1. It is a three-amino-acid peptide bound to a single copper ion, and the GHK sequence is not synthetic in origin — it occurs naturally inside type I collagen, the main structural protein in skin and tendon. When collagen is broken down during normal turnover, the freed GHK-Cu complex appears to act as a local signal calling in fibroblasts (matrix-making cells) to rebuild ^[6][7].

Of the two peptides on this desk, GHK-Cu has the stronger human evidence base. That evidence is mostly topical — creams and serums applied to the skin surface — and it has a built-in limitation: the peptide does not cross intact skin well on its own ^[1]. Topical copper-peptide products are legal cosmetic ingredients; injectable or whole-body systemic use is unapproved and research-only. This page summarizes the research literature, describes cautions plainly, and lists no human dose.

What it is

GHK-Cu is a linear tripeptide — glycyl-L-histidyl-L-lysine — chelated in a 1:1 ratio to a copper(II) ion. "Chelated" means the copper is gripped by multiple coordinating points: the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and the deprotonated amide nitrogen between glycine and histidine. The lysine side chain is left free, giving the molecule its small positive charge and its biological recognition properties.

The GHK sequence appears endogenously in two places: within the alpha-2(I) chain of type I collagen, and in a matrix protein called SPARC/osteonectin. This endogenous origin is the biological rationale behind GHK-Cu research: a sequence built into the scaffold, released as the scaffold remodels, potentially signaling that remodeling has begun and new matrix is needed ^[4][6]. Copper coordination is not optional for this activity — the free GHK tripeptide without copper does not reproduce key effects such as stimulating matrix metalloproteinase-2 in cell studies.

How it works

GHK-Cu acts on two levels simultaneously: as a copper chaperone and as a pleiotropic signaling molecule.

At very low concentrations — picomolar to nanomolar — it directly stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing the enzymes that degrade the matrix (matrix metalloproteinases, or MMPs) against their natural inhibitors (TIMPs). In plain terms: it turns up matrix production and fine-tunes the degradation side of the cycle ^[6]. The copper ion it carries enables lysyl oxidase — a cross-linking enzyme — to bolt newly made collagen and elastin fibers together, and the bound copper also shows superoxide-dismutase-like antioxidant activity.

At the gene level, a Connectivity Map analysis reported that GHK shifts expression of approximately 31.2% of human genes at a 50%-or-greater change threshold — roughly 59% of affected genes upward and 41% downward — with strong stimulation of the ubiquitin-proteasome (protein quality-control) system (41 genes up, 1 down), DNA-repair gene sets, and antioxidant programs ^[2]. A clarification belongs here: the widely quoted figure of "~4,000 genes" is an extrapolation from broader-threshold analyses; the verified number at the 50%-or-greater threshold is in the order of 2,100 genes.

Cell-type targets documented in the literature include dermal fibroblasts (collagen/elastin/GAG synthesis), keratinocytes, hair follicle dermal papilla cells, vascular endothelial cells (angiogenesis), lung fibroblasts (anti-fibrotic), intestinal epithelium (tight-junction support), and neurons (neurotrophic support) ^[6].

What the research shows

Foundational collagen stimulation. In a 1988 human fibroblast cell study, GHK-Cu (glycyl-L-histidyl-L-lysine-Cu2+) dose-dependently increased collagen synthesis; stimulation began between 10⁻¹² and 10⁻¹¹ M, peaked at 10⁻⁹ M, and was independent of any change in cell number — indicating a direct metabolic effect rather than simply more cells making the same amount of collagen ^[7].

Skin regeneration and matrix synthesis. A 2015 review documents GHK-Cu stimulating synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin, notes that plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by age 60, and reports topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in a direct-comparison trial. The same review documents placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density ^[4].

Tissue remodeling: the full profile. A 2008 review established GHK-Cu's multi-modal tissue-remodeling reach: stimulation of wound-healing protein synthesis (including VEGF, FGF-2, NGF, erythropoietin), chemotaxis of repair cells (macrophages, mast cells, capillary cells), suppression of free radicals, thromboxane, TGF-beta-1 and TNF-alpha, and inhibition of protein glycation ^[6].

Gene expression breadth. The 2018 Connectivity Map analysis quantified the broad transcriptomic shift: roughly 31.2% of human genes altered at a 50%-or-greater threshold, with the ubiquitin-proteasome system (protein quality control), DNA-repair and antioxidant programs most strongly upregulated ^[2].

Hair growth, controlled human trial. In a 6-month randomized trial of 45 men with androgenetic alopecia (Norwood-Hamilton stages II-V), a combination of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 hairs (at 100 mg/mL) and 71.5 hairs (at 50 mg/mL) versus only 9.6 for placebo (p<0.05), with no adverse events in any group ^[3]. This is the strongest controlled human efficacy signal for a GHK-containing topical; it is a combination product, not pure GHK-Cu.

Skin penetration, quantified. An ex vivo human skin-penetration study measured a copper permeability coefficient of 2.43 ± 0.51 × 10⁻⁴ cm/h from the GHK-Cu tripeptide; over 48 hours, 136.2 ± 17.5 µg/cm² of copper permeated dermatomed skin and 97 ± 6.6 µg/cm² was retained as a dermal depot ^[5].

The delivery challenge. The most recent comprehensive review (2025) confirms poor stratum-corneum permeability (calculated clogP of -2.24) as the central challenge for topical GHK-Cu, and evaluates palmitoylation (Pal-GHK, clogP 1.14) and microneedle pretreatment (approximately 134 nmol GHK permeated with microneedling versus essentially none through intact skin) as enhancement strategies ^[1].

Reported effects, cautions & safety

Topical copper-peptide products carry a long cosmetic safety record. The cautions that follow are drawn from the research literature and from clearly labeled community anecdotal reports.

Reported benefits (anecdotal, not clinical evidence): People using topical copper-peptide serums and creams very commonly describe firmer, more elastic-feeling skin after several weeks of consistent use; softer fine lines and shallower-looking wrinkles building gradually over 6-12 weeks; better hydration and a plumper look appearing within the first week or two; smoother texture and a brighter complexion; and — for those applying to the scalp alongside microneedling — less hair shedding and hair that looks thicker over 3-6 months. These are subjective observations from skincare and hair-loss communities, not measured clinical outcomes.

Reported adverse effects (anecdotal, not clinical evidence): The most common complaints are skin irritation (redness, itching, stinging, dryness), linked anecdotally to starting at too high a concentration or applying too frequently. Some acne-prone users report a transient breakout phase. A small group describes an effect nicknamed the "copper uglies," where skin appears worse rather than better; community consensus is that this is uncommon. Users who layer copper peptides with strong vitamin C, AHAs or retinol frequently report either irritation or a loss of effect.

Literature-based cautions:

• No approved drug indication. Topical copper tripeptide-1 (Copper Tripeptide-1) is a legal cosmetic ingredient. Injectable or systemic GHK-Cu is unapproved and research-only, with no validated human pharmacokinetic data behind any community dosing protocol ^[1].
• Copper coordination required. The intact GHK-Cu complex — not free GHK — is the form behind documented bioactivities. Products or conditions that strip copper from the complex may not behave as described in the literature.
• Vitamin C and low-pH acid incompatibility. Strong reducing agents (ascorbic acid) and acidic exfoliants can break the copper-peptide complex or compete for the copper ion, destroying both actives. These are best separated by time of day ^[1].
• Pigmentation variability. Because copper supports the enzyme tyrosinase in melanin production, a preclinical study showed increased tyrosinase activity and melanin output in pigment-cell lines. People with existing melasma or stubborn dark spots may experience inconsistent outcomes, and community reports run in both directions.
• Skin irritation risk at high concentration. Even in a controlled post-procedure study, individual tolerability varied. Patch-testing first is the common-sense approach ^[4].
• Single-group concentration in foundational literature. A large share of foundational GHK-Cu mechanistic and review work originated with one investigator and colleagues, which limits independent replication of the broader gene-expression and anti-aging claims ^[4].
• Human evidence is limited. The strongest human data are from small topical trials (n=13–71) and one 45-patient combination hair-loss RCT, and sweeping anti-aging promises should be held to that scale ^[3].

Where it fits in collagen and matrix research

GHK-Cu is the collagen-and-matrix specialist on this desk: a molecule literally built into the scaffold it helps maintain, with the broadest human evidence of the two peptides here — and with delivery science that is still catching up to its biology ^[1]. Its documented reach spans the matrix (collagen, elastin, GAGs, proteoglycans), the vascular supply (VEGF stimulation), the gene-expression landscape (ubiquitin-proteasome, DNA-repair, antioxidant programs), and the inflammatory environment (TNF-alpha, TGF-beta-1 suppression) ^[6]. Where BPC-157 enters the repair picture through angiogenesis and cytoprotection, GHK-Cu is the scaffolding story: construction, maintenance, and remodeling of the tissue matrix itself. See how they compare on the comparison page.